Baxter Launches Digital Image Capture Capability for PanOptic Plus Ophthalmoscope
16 Outubro 2023 - 10:00AM
Business Wire
- Helps support faster diagnosis, enabling earlier treatment of
eye conditions
- Enables a more digitally connected primary care exam
- Facilitates collaboration and education among primary care
clinicians, specialists, patients and family members
Baxter International Inc. (NYSE:BAX), a leader in patient
monitoring, physical assessment and vision screening products,
announced the launch of digital image capture capability for eye
exams using its existing Welch Allyn PanOptic Plus
Ophthalmoscope. The iExaminer Pro System adds a key
technology to routine eye exams, designed to help advance
healthcare professionals’ ability to examine and diagnose the eye
health of patients.
“Healthcare settings have never been more demanding, and
clinicians need their tools to offer improved efficiency and
accuracy that ultimately allows earlier care for patients,” said
Jim O’Connell, president, Front Line Care, Baxter. “The
iExaminer Pro System uses the latest tech, allowing
providers to spend more time focusing on the thing that matters
most – their patients.”
The PanOptic Plus Ophthalmoscope with iExaminer
Pro System adds the ability to connect a smart device to
capture images for further examination and enables clinicians to
move quickly from an optical exam to adding digital image capture.
When used with the iExaminer Pro App, clinicians can
securely save and share eye images for tracking and trending and
initiate more informed consultations with specialists.
“Examining the structure of the eyes is a critical part of
assessing patient health,” said Julie Jakubowski, M.D., F.A.C.P.,
head of medical affairs, Front Line Care, Baxter. “The
PanOptic Plus Ophthalmoscope with iExaminer
Pro System helps to enable healthcare providers to catch
issues early on in a primary care setting, easily collaborate with
specialists, and facilitates patients getting the diagnosis, care
and treatment they need in a timely manner.”
The iExaminer Pro System has been in use with Baxter’s
Welch Allyn MacroView Plus Otoscope since 2021. The addition
of digital image capture capability for eye exams represents the
company’s continued commitment to using connected devices to help
improve patient outcomes via routine physical exams.
The PanOptic Plus and MacroView Plus tools offer
clinicians bigger views compared to standard ophthalmoscopes and
otoscopes, plus additional key features such as long-lasting LED
lamps and DuraShock technology for durability.
The new offering is now available in the U.S. and will be
showcased at the upcoming American Academy of Pediatrics National
Conference & Exhibition (Oct. 20-24) and American Academy of
Family Physicians Family Medicine Experience conference (Oct.
26-29). Find more information and the full range of product
capabilities here.
About Baxter
Every day, millions of patients, caregivers and healthcare
providers rely on Baxter’s leading portfolio of diagnostic,
critical care, kidney care, nutrition, hospital and surgical
products used across patient homes, hospitals, physician offices
and other sites of care. For more than 90 years, we’ve been
operating at the critical intersection where innovations that save
and sustain lives meet the healthcare providers who make it happen.
With products, digital health solutions and therapies available in
more than 100 countries, Baxter’s employees worldwide are now
building upon the company’s rich heritage of medical breakthroughs
to advance the next generation of transformative healthcare
innovations. To learn more, visit www.baxter.com and follow us on
Twitter, LinkedIn and Facebook.
This release includes forward-looking statements concerning
potential benefits associated with the Welch Allyn PanOptic
Plus Ophthalmoscope with iExaminer Pro System. The
statements are based on assumptions about many important factors,
including the following, which could cause actual results to differ
materially from those in the forward-looking statements: demand for
and market acceptance for new and existing products; product
development risks; inability to create additional production
capacity in a timely manner or the occurrence of other
manufacturing or supply difficulties (including as a result of
natural disasters, public health crises and epidemics/pandemics,
regulatory actions or otherwise); satisfaction of regulatory and
other requirements; actions of regulatory bodies and other
governmental authorities; product quality, manufacturing or supply,
or patient safety issues; changes in law and regulations; and other
risks identified in Baxter's most recent filing on Form 10-K and
Form 10-Q and other SEC filings, all of which are available on
Baxter's website. Baxter does not undertake to update its
forward-looking statements.
Baxter, DuraShock, iExaminer Pro, MacroView Plus, PanOptic Plus
and Welch Allyn are trademarks of Baxter International Inc. or its
subsidiaries.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231016028030/en/
Media Contact Natalie Matthews, (224) 515-0219
media@baxter.com
Investor Contact Clare Trachtman, (224) 948-3020
Baxter (NYSE:BAX)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Baxter (NYSE:BAX)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024